Decision aid for RAI in thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have intermediate-risk differentiated thyroid cancer diagnosed in the last 6 months
- You have not had radioactive iodine treatment before
- You are not pregnant, breastfeeding, or have a low white blood cell count that would prevent RAI
- You are able to understand and take part in the study decisions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
This trial studies how well radioactive iodine treatment works for people with certain types of thyroid cancer that have a low or intermediate risk of coming back. It aims to see if this treatment is effective and safe for these patients.
This study looks at how different doses of radioactive iodine affect people with thyroid cancer after they have had their thyroid removed. It may help doctors choose the best dose for future patients.
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
This study looks at how people make decisions after a thyroid cancer diagnosis. It aims to understand what matters to patients when choosing treatment, which may help improve care for others in the future.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.